Atlas Trials

PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers

Clinical trial NCT02936323 · COMPLETED

Trial details

NCT number
NCT02936323
Sponsor
Tarveda Therapeutics
Status
COMPLETED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Neuroendocrine TumorsCarcinoma, Small Cell LungNeuroendocrine Carcinoma
Start date
2016-12-08
Primary completion
2020-07-31
Enrollment
89

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.